Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
Prevail Therapeutics raises $50M for gene therapy in Parkinson’s, other neurodegenerative disorders
The company hopes the funding will move it toward the clinic. Active clinical programs of gene therapies in Parkinson's include efforts by Voyager Therapeutics and a university in Japan.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Maze Therapeutics launches with nearly $200M to explore genetic modifiers’ role in disease
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.
Polaris Partners launches Dewpoint Therapeutics with $60M round
The company will focus on what it called a previously unexplored field in drug discovery, membrane-less cell organelles called biomolecular condensates
Relay Therapeutics hits VC jackpot with $400M Series C round for protein motion drug discovery
The round, led by SoftBank Vision Fund, is more than six times the size of Relay's Series B round, which it closed in December 2017.
RNA metabolism-focused Gotham Therapeutics launches with $54M Series A round
The company, focused on epitranscriptomics, launched with backing from Versant Ventures, Forbion, GSK's venture capital arm, Celgene and others.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
System1 Biosciences raises $25M in Series A round for neurotherapeutics discovery platform
System1 Biosciences' platform combines stem cell lines from patients with brain diseases with a three-dimensional in vitro system and data analytics.
Epic Sciences raises $52M Series E round to advance liquid biopsy diagnostics
The San Diego-based firm plans to integrate its "No Cell Left Behind" platform with electronic medical records and big data analytics.
Neurology startup Magnolia Neurosciences raises $31M in Series A round
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer's disease.